Seres Therapeutics develops bacterial consortia to treat disease by interacting with host cells and tissues. Its lead product candidate, SER-109, has completed a Phase III clinical trial for treating clostridium difficile infection. The company is also developing other microbiome drugs to treat gastrointestinal infections, graft versus host diseases, ulcerative colitis, metastatic melanoma, and clostridioides difficile infection.